The Supervisory Board of Sartorius AG has extended the appointment of Dr. René Faber as a member of the Executive Board by a five-year period to December 31, 2031. Faber, 50, holds a Ph.D. in polymer chemistry from the Technical University of Munich and has been with the company since 2002. He assumed his current role in January 2019, overseeing the Bioprocess Solutions Division, which is a key driver of the company's growth in the biopharmaceutical sector.
This extension underscores Sartorius's commitment to stable leadership during a period of expansion and innovation. The Bioprocess Solutions Division provides single-use solutions for the production of biotech drugs, vaccines, and cell and gene therapies, areas that have seen surging demand. The division's performance is critical as Sartorius reported sales revenue of approximately €3.5 billion in 2025, with over 14,000 employees worldwide.
Faber's continued leadership is expected to support the company's strategic goals, including portfolio expansions through acquisitions and advancements in sustainable manufacturing. His deep expertise in polymer chemistry aligns with Sartorius's focus on developing safer and more efficient bioprocessing technologies. The company's financial calendar highlights upcoming results announcements, including first quarter results on April 23, 2026, half-year results on July 23, 2026, and nine-month results on October 22, 2026.
Sartorius, headquartered in Göttingen, Germany, operates around 60 production and sales locations globally. The company's Lab Products & Services Division also serves research and quality assurance laboratories. For more information, visit the company's newsroom or follow Sartorius on LinkedIn.
